Several months ago, a company called Electro-Optical Sciences (MELA) began developing a device to better screen for skin cancer. Anticipation of the trial results pushed the stock to almost $10. Again, investors got excited... but our Ph.D. knew the device would never make it past the FDA. Sure enough, he made a quick 60% profit.

» For example, just a few weeks ago you could have made 770% gains in just a few weeks with Biomarin Pharmaceuticals (BMRN) and its failed drug "6R-BH4".

» 6 days later, you could have made 823% gains in minutes with a company called Viopharma Inc. (VPHM) and its failure named Maribavir.

» And less than 2 days after that, you could have made a modest 72% in a day with a little company called Synta Pharmaceuticals (SNTA) when they failed their Phase III trial.

Best of all, you could have known approximately when these drug failures would have happened – BEFORE they were announced to the public.

But how?

And how does all of this relate to the new prostate cancer vaccine, I mentioned earlier?

I'll show you...

What the medical establishment doesn't
want you to know...
According to our Ph.D., the drug and pharmaceutical industry's "clinical review process" is severely rigged.

And it's because of this "rigged" system that you have an extraordinary opportunity to make a lot of money.

Let me explain...

I'm sure I don't have to tell you that one of the most profitable things you can do in America is develop a new drug to treat just about any type of disease.

The rewards are simply staggering...

Did you know, for example, that drug companies can charge about $20,000 per year for ordinary drugs to fight various diseases?

And did you know that if you need treatment for diseases like breast cancer, the drugs you need can cost as much as $50,000 a year?

Incredible, isn't it?

And even that staggering figure is peanuts compared to California-based Biomarin's genetic disease treatment, Aldurazyme, which costs a whopping $100,000 a year!

That's why it's no surprise that drug companies make so much money. In one recent year, for example, as hard as it is to believe, the top 10 drug makers in the Fortune 500 made more money than all of the other 490 companies combined.

Can you imagine that... the 10 biggest drug companies made more money than Wal-Mart, Coke, IBM, Home Depot, Microsoft, McDonald's, Exxon, and the rest of the Fortune 500 companies... COMBINED!

In short, selling drugs in America is basically highway robbery – a license to print money...

But here's the dirty little secret drug companies don't want you to know...

MSNBC says: FDA is rejecting more new drugs There's no doubt about it. It's getting harder for companies to get their drugs through clinical trials. In fact, last year the FDA only approved 18 new drugs – the lowest number since 1983. Here are just a few recent news stories about the low FDA approval rates: Vanda shares dive 73% to 90 cents; FDA rejects Rockville biotech's Schizophrenia drug The Baltimore Sun, July 2008 FDA says cancer test failed to get its approval New York Times, October 2008 FDA rejects Neurocrine's insomnia drug – Stock falls 50% The San Diego Union Tribune, December 2007 FDA panel rejects drug for breast cancer; Genentech shares plunge LA Times, December 2007 Stock tumbles on FDA rejection "Boston Globe, November 2007 FDA rejects Abbott cancer pill Chicago Tribune, September 2005 An FDA panel advisory rejects 2 cancer drugs New York Times, May 2004

In order to find a drug that they can get through the clinical review process, drug companies take the "shotgun approach"... most of which fail.

You see, in the clinical review process, 8 out of every 10 new drugs fail their clinical tests. In fact, there are other, more specific types of drugs that fail a whopping 9 out of 10 times (more on this in a moment).

How can 80% of new drugs fail... yet drug companies still make so much money?

Well, the truth is, the drug companies don't care if most of their tests fail.

That's why these firms go public in the first place, and bring in hundreds of millions from shareholders.

What I mean by that is, when drug companies go public, and get listed on the stock market, they are able to use hundreds of millions of dollars from ordinary shareholders to fund their work.

Then, they simply submit one "long-shot" drug after another, sometimes copying a drug that's already out there, in hopes that the overworked Food & Drug Administration (FDA) will allow one to get through.

For example, the vast majority of "Big Pharma" companies' drugs, like New York-based Bristol-Myers Squibb's, NEVER make it past clinical trials. But a few years ago, they finally found one that did. Today its cancer drug, Erbitux costs EACH patient a whopping $50,000 a year!

The point is, drug companies know full well that 8 out of every 10 new drugs will fail in clinical trials.

And herein lies our opportunity...

"It's always far easier to say no
to a drug than yes."

-- Dr. David A. Kessler, Director of the FDA (1990 –1997)

Most investors think the way to make money in the biotech world is to find a promising new drug, and hope the company is successful spending millions of dollars getting it past the FDA.

Like the new prostate cancer vaccine I've been talking about in this letter.

But remember, 8 out of every 10 new drugs fail in clinical trials – so the odds are stacked heavily against you making money on these investments. Maybe you've had the experience in your own investment career...

You hear about a great company with a great story about a promising new drug. Problem is, these new drugs fail in clinical tests, 80% of the time.

What most investors don't know, however, is that you could make a fortune every time one of these new drugs fails. And because new drugs fail 80% of the time... well... you could make an absolute fortune in a very short amount of time.

Just take a look at the drug trial our Ph.D. drug expert showed us in the past 60 days alone. Note the gains you could have made in 24 hours or less, in the column to the right:


The average gain on this list is over 408%.

What's more, you could have pocketed these gains nearly 20 TIMES during the worst market conditions of the past 80 years.

Imagine that... a $1,000 stake on each one of these drugs would be worth roughly $77,520 in just a few months time.

But believe it or not, it gets a lot better...

More than 14-times your money in a single afternoon
Every big drug company has its "magic pill."

Pfizer has Lipitor. Wyeth has Effexor. Merck has Singulair.

AstraZeneca (AZN) – the British drug company – has a lung cancer drug called Iressa.

It's their "magic pill"... their cash cow. They sell it for $10,000 a pop.

The company loves to talk about the "success" of Iressa.

But what they fail to mention is that you could have made a lot of money, many times over the past few months, after the company's stock plunged on several drug failures.

Have a look in the chart below...


We estimate you could have DOUBLED your money at least seven times over the past year with this company's clinical drug trial failures...

In fact, see that last bit of "bad news" all the way to the right on the chart? That alone represents a 1,480% gain (in a single afternoon) with a "failed" drug called Zactima.

But that's not all our expert showed us...

The same is true for a drug maker called Elan (ELN). We estimate several QUADRUPLE-digit gain opportunities over the past few years with this company's drug trial failures...


Or how about Pain Therpeutics (PTIE), who's put together an "impressive string of losers" as well. We estimate at least SEVEN opportunities to TRIPLE your money since 2004.


The point is, it's a lot easier to make money predicting the drug failures than successes.

You can easily make a lot of money by betting against the success of these very sophisticated and risky clinical drug trials.

And these opportunities are everywhere. You just have to know where to find them.

In fact, if you simply bet against every single one in the stock market, then you'd be right approximately 80% of the time.

But in reality, you can increase your odds to much higher than 80% when you focus on a small sub-sector of the drug market.

The cancer vaccine I mentioned at the beginning of this letter is a perfect example.

This class of drug has NEVER been approved by the FDA... ever.

That's over 72 years of attempts by the drug companies and not one has made it through the regulatory and clinical gauntlet.

And that's what our Ph.D.'s April 30th trade is all about...

But first, how do we know the announcement will happen on this exact date?

Know ahead of time when these gains will likely take place...
As I mentioned, on April 30th we expect this small company to announce the failed results of their new cancer vaccine...

And the stock to crash...

But how do we know when this announcement will take place?

You see, our expert has spent the better part of the last decade working in academic institutions, as a contractor with the U.S. government, and with private firms. In each position, he worked closely with the Federal Agency behind these clinical drug trials.

In short, because he knows the detailed inner-workings of the "clinical review process" – and because he has a large "inner circle" of medical contacts and research avenues – he is able to find out when these results will be announced, down to the day in most cases.

Consider the case of Rigel Pharmaceuticals (RIGL)...

This company's shares plunged on October 27th on the news that its drug for rheumatoid arthritis – called R788 -- failed in clinical trials...

How did our expert know to trade on that date beforehand?

On Oct 21st – a full 6 days before the trial results were announced – our expert was able to obtain this statement from the company:

"On October 27th from 2:00 – 3:00pm Pacific Time members of Rigel's senior management team will provide an update on the company's lead product candidate, R788..."

That means that you could have known the exact day and time the announcement was to take place – a full 6 days before it happened!


Investors who capitalized on this information could have made over 1,345% as the stock crashed in just a few minutes time.

Here, let me show you another example...

579% gains in less than 24 hours
On November 17th, shares of a company called United Therapeutics (UTHR) sank on the news that its hypertension drug, called "Remodulin," failed in clinical trials.

Of course, our Ph.D. knows the dirty little secret of the medical establishment – and that the trial would likely fail (remember, 80% of drugs in clinical trials fail)...

But how did he know the November 17th announcement date?

Because on October 30 – a full 2 weeks before the failed drug trial – our Ph.D. got this statement from the company:

"We expect to announce the preliminary results of the [Remodulin] trial in mid-November."

The chart below illustrates how you could have capitalized on this information:


Investors who took advantage of this information could have made over 579% as the stock tumbled.

Best of all, it would have only taken a few minutes to realize those gains.

Here's another example...

"300% gains in a day
On December 11th, shares of Pain Therapeutics (PTIE) plunged on news that its experimental pain drug, Remoxy failed in clinical trials.

Of course, our inside expert knew this was going to happen... weeks beforehand.

On October 29th – more than a full month before the announcement took place – he was able to get in touch with the company and obtain this information:

The FDA is expected to complete its review of the REMOXY NDA in December 2008."

Not surprisingly, shares took a dive on December 11th, netting investors who took advantage of this opportunity 300% gains in a single day!


Incredible, right?

Most recently, our expert obtained the official announcement date for the company developing the prostate cancer vaccine.

April 30th... just a few weeks from today.

Let me tell you a little bit more about this opportunity...

It all begins this April...
Our expert sees 3 main reasons this drug won't make it past the FDA:

Reason #1 – The clinical trials are severely flawed

This new cancer treatment is specifically designed for patients in the early stages of prostate cancer. But here's the thing. FDA regulations don't allow early-stage cancer patients to even participate in clinical trials because there are BETTER treatments available!

Amazing, right?

That means the patients currently in the trial are all late-stage patients, and therefore too sick for the drug to work effectively. The trial results will come back negative.

But don't take just our expert's word for it. A recent article in FDA Consumer Magazine – an industry trade journal -- made this compelling point:

"The best settings are for treating people who have minimal disease or a high risk of recurrence. But at this time, most [drugs in this class] are being studied in people who have failed other therapies." ~ Jeffrey Schlom, Ph.D.

BusinessWeek said it like this:

"It's nearly impossible to pinpoint the right patients for a drug [trial]... but the wrong patients cause the trial to fall short of it's goal, and the drug isn't approved"

So as you can see, just getting the right trial patients is tough enough, but there are other problems...

Reason #2 – This drug has already failed an FDA trial.

This new drug already failed a phase III clinical trial, the final step before government approval, in 2005. However, the drug was given another chance by the FDA.

In other words, the proof would need to be so strong that the FDA would have to be willing to reverse its previous decision... and as you can imagine, that's just not going to happen.

Reason # 3 – The FDA has NEVER approved this type of drug before.

Finally, the FDA, in its 72-year history, has never, ever approved a drug in this class. Considering the clinical trial flaws and past failures, our expert told us "I find it highly unlikely the FDA will approve this vaccine."

In fact, we found and FDA publication that backed up this fact:

Pub No. FDA 04-1338C

"[The drug class] is experimental; none have been licensed by the Food and Drug Administration"

What's more, the company developing this new drug is just a small $300 million company. This new treatment is the only drug with potential in its pipeline.

A rejection by the FDA will bankrupt this small firm. And give investors with the right information a chance to triple their money in less than 30 days.

So how can you take advantage of this situation right away?

Our expert and his team have created an investment research service based on this new breakthrough
We think our expert's strategy is so powerful and so potentially life-altering that we want him share it with our readers on a regular basis.

So...

We inked a deal with him to give our readers access to all his upcoming "clinical trial" trades for at least the next 12 months.

We call this investment research service, the S&A FDA Report.

As an FDA Report member, you'll receive a list of potential plays – the dates and ticker symbols of companies with upcoming clinical trial results announcements... just like the one's mentioned throughout this letter.

Our expert calls it his "Crash List."

Each month, he personally compiles a list of upcoming "clinical trial" announcements, using his knowledge of the "clinical review process" and his numerous "contacts" inside the medical community...

Here's a sneak peak at the Current "Members Only" Crash list:
Will our expert recommend a play on every single one of these announcements?

Well, remember that if you bet on every single one you'll likely win 80% of the time.

But that's not what FDA Report is all about.

Excited about your "Crash List" "Great research!!" ~ Bill Weston "I am excited about your crash list. Thanks for adding this feature to an already excellent product." ~ Sidney McElheney "I wanted to write and say thank you for your recommendations." ~ David Katts

Remember, when you look deeper into the "clinical review process" – as our expert does – there are ways to increase your odds to much higher than 80%.

For example, part of our expert's strategy revolves around a specific type of drug that fails in clinical trials 92% of the time.

In fact, right now there are more treatments in the "drug review" pipeline for this disease, than any other. So, there will be plenty of opportunities to make money on this phenomenon over the next several months.

He also knows about a very small, "niche" type of clinical trial where new drugs fail TWICE as often as in other trials. In fact, he'll be reporting on companies with drugs in these clinical trials as well. They don't happen very often, but when they do you could make a lot of money.

In fact, there's another specific type of drug you can look for that even if it passes clinical trials, it's likely that the FDA won't give its final seal of approval.

Don't forget, the FDA has NEVER before approved the type of drug involved in the April 30th decision. And we don't think they'll start now.

The FDA Report will be focusing on these "high probability" events –and so much more.

Obviously, I can't get into the specifics of which drugs or clinical trials our expert will report on. We've paid handsomely to obtain his medical trade knowledge and to keep him exclusively ours. Therefore this information is for FDA Report readers only.

So What's Next?
To access your copy of the members only "Crash List," along with the exact strategy to take advantage of the April 30th deadline, just follow the link pasted at the end of this letter.

This list is for your own personal use. We'll assume by accepting your membership you're also giving us your word this list will not fall into the hands of anyone else.

Next you'll have immediate online access to our report about the April 30th opportunity. This easy to read report will walk you step by step through the trade and exactly how to play it to see maximum gains.

It's called America's Next Major Stock Crash. Claim your membership today to gain immediate access to this new report.

Then in addition to the monthly issues that are delivered straight to your inbox on the third Wednesday of every month, our expert will provide you with e-mail updates on any upcoming clinical trial announcements. He will tell you exactly which plays offer the biggest rewards month after month.

Finally, take a look at what a few of the FDA Report readers are saying about the member's only service:

"Patience and luck paid off with the IDEV acquisition announced earlier this week. I sold my stake for a 186% gain." ~ Henry Chatsworth

"I like the letter everything you recommended that I acted on has worked out. Thanks" ~ Ned Sutherland

"I like the FDA Crashlist approach. I watched the Alpharma/King drama unfold with great interest. Bring us more!" ~ Dan Sykes

Next, to get started with the big April recommendation and all other upcoming plays, here's what to do:

1. First, use our expert's "Crash List" to mark the upcoming announcement dates. You'll receive a new and updated "List" each month (You'll get access to the latest "List" as soon as you sign up).

This list is delivered monthly in the FDA Report issues. Keep it handy so you can reference it when our expert emails you. Put it on your fridge or tack it on your computer.

2. Then, wait for his email. He'll tell you whether or not to take action on each date you've marked down.

3. Finally, when our expert recommends you take action on a "clinical trial" event... he'll send you an email, telling you exactly what to say to your broker.

That's it.

We've set up this research service so that all the hard work is done for you.

So, how much does FDA Report cost?

Well, considering the amount of time, money, and energy it's taken us to get this strategy to our readers – not to mention the potential money that can be made – we could easily charge $5,000 a year for this research service... and it'd still be a bargain.

The price for one year of FDA Report research is $2,400. But if you sign up before March 30th, I'd like to give you an even better deal. When you sign up today, you'll receive a full year of FDA Report research and special reports for just $1,400.

You'll then have 90 days to decide whether his research is right for you. If for whatever reason you want to cancel your subscription in the first ninety days, just let us know. We'll give you a full refund. After all, if you like our work and think our investing strategy is right for you, then you stick around with us and S&A continues growing as a business.

Special Report: America's Next Major Stock Crash: You will have immediate access to our report about the April 30th opportunity. This easy to read report will walk you step by step through the trade and exactly how to play it to see maximum gains.

Special Report: How to Make a Fortune Trading Drug Disasters: Remember, this special members-only report represents your "drug crash" trading bible. Read it right away, before you review anything else. You'll learn the full details of the "clinical review process", information that few outside the medical community have ever seen... and the secrets behind our expert's strategy for optimizing potential returns on these recommendations.

FDA Report "Crash List": This members-only list details upcoming "clinical trial" results announcements over the next few weeks. You'll receive a new and updated "List" each month sent to you directly by our expert Again, you'll find this list in FDA Report monthly issues. Nothing quite like this exists elsewhere in the financial world.

FDA Report Trading Alerts: Once our expert acquires an upcoming announcement he'll monitor the situation closely, waiting for all the essential elements to fall into place. When it does, he'll send you an email with specific instructions – when and how to get in at the right price, how long to hold, and the likely gains you can expect to see.

FDA Report Trading Primer: Profiting from drug failures is just one of the trading strategies our expert has "picked up" over the years. There are several more unique ways to make money "at the hands" of the FDA that I didn't have time to go over in this letter. That's the purpose of this Special Report. He'll keep you updated on these investment strategies as well.

I hope you'll decide to join us.

To take advantage of this unique opportunity, Subscribe Now

Sincerely,



Brian Hunt
Editor In Chief, S&A Research
March, 2009

P.S. Don't forget, our expert has identified a clinical trial announcement taking place on April 30th. To see the best results, it is crucial that you get in as early as possible. The sooner you get in, the more money you're likely to make.

P.P.S. We're offering a special discount to all FDA Report members who sign up before March 30th. See order form for complete details.

P.P.P.S. Please feel free to check out the FDA Report's most frequently asked questions...